← Back to Clinical Trials
Recruiting NCT07226804

NCT07226804 Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07226804
Status Recruiting
Phase
Sponsor M.D. Anderson Cancer Center
Condition Thyroid Nodules
Study Type OBSERVATIONAL
Enrollment 30 participants
Start Date 2025-11-14
Primary Completion 2028-08-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Questionnaire

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 30 participants in total. It began in 2025-11-14 with a primary completion date of 2028-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To observe the outcomes of nsPFA therapy to treat benign thyroid nodules.

Eligibility Criteria

Eligibility Criteria * Scheduled to undergo ultrasound guided nsPFA as standard of care * Age 18 to 80 years. * Capable of providing independent consent. * Presence of biopsy-confirmed benign thyroid nodule , defined as one of the following: * Benign FNA X 2 or * Benign US guided FNA X 1 + benign thyroid nodule ultrasound appearance (TI-RADS 2) or * Benign FNA X 1 and radiographic/laboratory evidence of functional nature * Nodule measuring \>2cm in greatest dimension * Presence of compressive symptoms reasonably attributable to thyroid nodule (i.e. pressure sensation, dysphagia, dysphonia, respiratory distress) * No abnormal cervical lymph nodes during screening visit . Exclusion Criteria * Age \<18 * Patients considered unsuitable for nsPFA by the treating physician

Contact & Investigator

Central Contact

Victoria E Banuchi, MD

✉ vebanuchi@mdanderson.org

📞 346-217-8668

Principal Investigator

Victoria E Banuchi, MD

PRINCIPAL INVESTIGATOR

M.D. Anderson Cancer Center

Frequently Asked Questions

Who can join the NCT07226804 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Thyroid Nodules. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07226804 currently recruiting?

Yes, NCT07226804 is actively recruiting participants. Contact the research team at vebanuchi@mdanderson.org for enrollment information.

Where is the NCT07226804 trial being conducted?

This trial is being conducted at Houston, United States.

Who is sponsoring the NCT07226804 clinical trial?

NCT07226804 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Victoria E Banuchi, MD at M.D. Anderson Cancer Center. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology